Angiotensin-(1–7) and angiotensin-(1–9): function in cardiac and vascular remodelling
- 26 February 2014
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 126 (12) , 815-827
Abstract
The RAS (renin–angiotensin system) is integral to cardiovascular physiology; however, dysregulation of this system largely contributes to the pathophysiology of CVD (cardiovascular disease). It is well established that AngII (angiotensin II), the main effector of the RAS, engages the AT1R (angiotensin type 1 receptor) and promotes cell growth, proliferation, migration and oxidative stress, all processes which contribute to remodelling of the heart and vasculature, ultimately leading to the development and progression of various CVDs, including heart failure and atherosclerosis. The counter-regulatory axis of the RAS, which is centred on the actions of ACE2 (angiotensin-converting enzyme 2) and the resultant production of Ang-(1–7) [angiotensin-(1–7)] from AngII, antagonizes the actions of AngII via the receptor Mas, thereby providing a protective role in CVD. More recently, another ACE2 metabolite, Ang-(1–9) [angiotensin-(1–9)], has been reported to be a biologically active peptide within the counter-regulatory axis of the RAS. The present review will discuss the role of the counter-regulatory RAS peptides Ang-(1–7) and Ang-(1–9) in the cardiovascular system, with a focus on their effects in remodelling of the heart and vasculature.Keywords
This publication has 112 references indexed in Scilit:
- Regional mechanics determine collagen fiber structure in healing myocardial infarctsJournal of Molecular and Cellular Cardiology, 2012
- Angiotensin-(1–7) abrogates mitogen-stimulated proliferation of cardiac fibroblastsPeptides, 2012
- AVE0991, a Nonpeptide Compound, Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation via Induction of Heme Oxygenase-1 and Downregulation of p-38 MAPK PhosphorylationInternational Journal of Hypertension, 2012
- Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal InjuryInternational Journal of Hypertension, 2012
- Differential Mechanisms of Ang (1-7)-Mediated Vasodepressor Effect in Adult and Aged Candesartan-Treated RatsInternational Journal of Hypertension, 2011
- Chronic treatment with angiotensin‐(1‐7) improves renal endothelial dysfunction in apolipoproteinE‐deficient miceBritish Journal of Pharmacology, 2011
- Angiotensin1‐9 antagonises pro‐hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptorThe Journal of Physiology, 2011
- Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinasesExperimental Physiology, 2011
- Different Effects of Angiotensin II and Angiotensin-(1-7) on Vascular Smooth Muscle Cell Proliferation and MigrationPLOS ONE, 2010
- Alteration of sarcoplasmic reticulum Ca2+ release termination by ryanodine receptor sensitization and in heart failureThe Journal of Physiology, 2009